Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Cory Kasimov is an analyst at Evercore ISI Group. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/22/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | MRNA | Buy Now | Moderna | $121.30 | -1.07% | $120 → $120 | Maintains | In-Line | Get Alert |
| 05/14/2024 | ACLX | Buy Now | Arcellx | $62.56 | 35.87% | → $85 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | BBIO | Buy Now | BridgeBio Pharma | $26.19 | 90.91% | → $50 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | NBIX | Buy Now | Neurocrine Biosciences | $145.69 | 20.12% | → $175 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | MRNA | Buy Now | Moderna | $121.30 | -1.07% | → $120 | Initiates | → In-Line | Get Alert |
| 05/14/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | 8.12% | → $1150 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $84.09 | 34.38% | → $113 | Initiates | → Outperform | Get Alert |
| 05/14/2024 | BNTX | Buy Now | BioNTech | $86.02 | 16.25% | → $100 | Initiates | → In-Line | Get Alert |
| 02/27/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $42.55 | 106.82% | $84 → $88 | Maintains | Overweight | Get Alert |
| 06/05/2023 | KRTX | Buy Now | Karuna Therapeutics | — | — | $260 → $250 | Maintains | Overweight | Get Alert |
| 02/11/2022 | RARE | Buy Now | Ultragenyx Pharmaceutical | $42.55 | 210.22% | → $132 | Upgrade | Neutral → Overweight | Get Alert |
| 01/05/2022 | CERE | Buy Now | Cerevel Therapeutics Hldg | $42.90 | 16.55% | → $50 | Initiates | → Overweight | Get Alert |
| 12/21/2021 | BIIB | Buy Now | Biogen | $226.40 | 21.91% | $324 → $276 | Maintains | Neutral | Get Alert |
